Life sciences patent owners face a transformed inter partes review environment at the USPTO
The Long Read: Kramer Levin’s Hannah Lee and Irena Royzman look at how changes at the PTAB are playing out for companies in the sector caught up in litigation, while setting out crucial strategic insights that can help both rights holders and petitioners prevail.
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.